In a bold move, Trump recently signed an executive order aimed at reducing prescription drug prices in the U.S., challenging companies to lower their costs by referencing pricing in other countries. However, experts have expressed skepticism about the efficacy of this plan, suggesting it may lack the necessary enforcement mechanisms to achieve meaningful reductions. The order also includes a demand for drugmakers to respond within 30 days, but many analysts believe that Trump’s approach could face significant hurdles in implementation. Additionally, the pharmaceutical industry has voiced criticism, warning that while the intention may be to lower costs, the action could inadvertently harm smaller pharmacies and disrupt market dynamics. Meanwhile, Trump’s order has sparked discussions about the broader implications for big pharma and the ongoing debate over how to balance market freedom with price control. As the situation develops, stakeholders and healthcare professionals continue to monitor the potential impacts on both consumers and the pharmaceutical sector.